4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Spero Therapeutics, Inc. (SPRO) operates in the Biotechnology industry and is headquartered in Cambridge, United States with about 25 employees. Its market capitalization is roughly $123 million. In the fiscal year ended 2025-12-31, SPRO reported $60M in revenue and $9M in net income.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.
Interactive charts & full statements → Open the SPRO valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $60M | $27M | $97M | $49M | — |
| Operating Income (EBIT) | $7M | ($72M) | $27M | ($31M) | — |
| Net Income | $9M | ($69M) | $23M | ($46M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $40M | $3M | $12M | $5M | — |
| Operating Income (EBIT) | ($8M) | $31M | ($7M) | ($2M) | ($15M) | — |
| Net Income | ($7M) | $32M | ($7M) | ($2M) | ($14M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $69M | $110M | $182M | $125M | — |
| Total Liabilities | $10M | $64M | $76M | $49M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive SPRO viewer.
About TickerBase · Data methodology & sources